Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, ...

People with type 2 diabetes using GLP-1s had a lower risk for colorectal cancer than those undergoing bariatric surgery, as well as the general population.